Cargando…

Correction to: Mitigating Disparity in Healthcare Resources Between Countries for Management of Hereditary Angioedema

Detalles Bibliográficos
Autores principales:	Jindal, Ankur Kumar, Reshef, Avner, Longhurst, Hilary, Management), GEHM workgroup (Global Equity in H. A. E.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer US 2021
Materias:	Correction
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8496600/ https://www.ncbi.nlm.nih.gov/pubmed/34196910 http://dx.doi.org/10.1007/s12016-021-08869-y

Ejemplares similares

Mitigating Disparity in Health-care Resources Between Countries for Management of Hereditary Angioedema
por: Jindal, Ankur Kumar, et al.
Publicado: (2021)

Biomarkers in Hereditary Angioedema
por: Porebski, Grzegorz, et al.
Publicado: (2021)

Management of hereditary angioedema in resource-constrained settings: A consensus statement from Indian subcontinent
por: Jindal, Ankur Kumar, et al.
Publicado: (2023)

Management of acute attacks of hereditary angioedema: potential role of icatibant
por: Longhurst, Hilary J
Publicado: (2010)

Treatment of hereditary angioedema—single or multiple pathways to the rescue
por: Valerieva, Anna, et al.
Publicado: (2022)

Prodromes predict attacks of hereditary angioedema: Results of a prospective study
por: Leibovich‐Nassi, Iris, et al.
Publicado: (2022)

Optimum Use of Acute Treatments for Hereditary Angioedema: Evidence-Based Expert Consensus
por: Longhurst, Hilary
Publicado: (2018)

Elevated D-dimers in attacks of hereditary angioedema are not associated with increased thrombotic risk
por: Reshef, A, et al.
Publicado: (2015)

An update on the genetics and pathogenesis of hereditary angioedema
por: Banday, Aaqib Zaffar, et al.
Publicado: (2019)

Hereditary Angioedema: Diagnostic Algorithm and Current Treatment Concepts
por: Jindal, Ankur Kumar, et al.
Publicado: (2021)

Hereditary angioedema with C1 inhibitor deficiency: delay in diagnosis in Europe
por: Zanichelli, Andrea, et al.
Publicado: (2013)

Continued icatibant use across recurrent attacks in adolescents with hereditary angioedema
por: Farkas, Henriette, et al.
Publicado: (2021)

WAO Guideline for the Management of Hereditary Angioedema
por: Craig, Timothy, et al.
Publicado: (2012)

Canadian hereditary angioedema guideline
por: Betschel, Stephen, et al.
Publicado: (2014)

Lanadelumab demonstrates rapid and sustained prevention of hereditary angioedema attacks
por: Riedl, Marc A., et al.
Publicado: (2020)

85 Clinical Efficacy of Recombinant Human C1 Inhibitor in Patients with Acute Hereditary Angioedema Attacks
por: Reshef, Avner, et al.
Publicado: (2012)

Long-Term Efficacy of Subcutaneous C1 Inhibitor in Pediatric Patients with Hereditary Angioedema
por: Levy, Donald, et al.
Publicado: (2020)

Recombinant human C1 esterase inhibitor treatment for hereditary angioedema attacks in children
por: Reshef, Avner, et al.
Publicado: (2019)

A Review of Randomized Controlled Trials of Hereditary Angioedema Long-Term Prophylaxis with C1 Inhibitor Replacement Therapy: Alleviation of Disease Symptoms Is Achievable
por: Longhurst, Hilary J, et al.
Publicado: (2023)

Hereditary Angioedema Attacks Resolve Faster and Are Shorter after Early Icatibant Treatment
por: Maurer, Marcus, et al.
Publicado: (2013)

Treatment patterns and healthcare resource utilization among patients with hereditary angioedema in the United States
por: Riedl, Marc A, et al.
Publicado: (2018)

Hereditary angioedema
por: Lesser, Helen, et al.
Publicado: (2021)

Hereditary Angioedema
por: Banerjee, Anjali, et al.
Publicado: (2023)

Comparing acquired angioedema with hereditary angioedema (types I/II): findings from the Icatibant Outcome Survey
por: Longhurst, H. J., et al.
Publicado: (2017)

The International/Canadian Hereditary Angioedema Guideline
por: Betschel, Stephen, et al.
Publicado: (2019)

Attenuated androgen discontinuation in patients with hereditary angioedema: a commented case series
por: Maurer, Marcus, et al.
Publicado: (2022)

Assessment and management of disease burden and quality of life in patients with hereditary angioedema: a consensus report
por: Bork, Konrad, et al.
Publicado: (2021)

Impact of lanadelumab on health‐related quality of life in patients with hereditary angioedema in the HELP study
por: Lumry, William R., et al.
Publicado: (2020)

Development and content validity testing of a patient-reported outcomes questionnaire for the assessment of hereditary angioedema in observational studies
por: Bonner, Nicola, et al.
Publicado: (2015)

Editorial: C1 inhibitor deficiency and angioedema
por: Farkas, Henriette, et al.
Publicado: (2022)

Hereditary angioedema in women
por: Bouillet, Laurence
Publicado: (2010)

Hereditary Angioedema: Not An Allergy
por: Bhivgade, Sanjay, et al.
Publicado: (2012)

The Pathophysiology of Hereditary Angioedema
por: Zuraw, Bruce L
Publicado: (2010)

Pediatric hereditary angioedema
por: MacGinnitie, Andrew J
Publicado: (2014)

Hereditary angioedema in childhood
por: Ahn, Young Min
Publicado: (2020)

Lanadelumab for hereditary angioedema
Publicado: (2022)

Real-world outcomes in hereditary angioedema: first experience from the Icatibant Outcome Survey in the United Kingdom
por: Longhurst, Hilary J., et al.
Publicado: (2018)

Correction to: The International/Canadian Hereditary Angioedema Guideline
por: Betschel, Stephen, et al.
Publicado: (2020)

Screening for type II hereditary angioedema—the “poor man’s c1-inhibitor function”
por: Jindal, Ankur Kumar, et al.
Publicado: (2023)

2010 International consensus algorithm for the diagnosis, therapy and management of hereditary angioedema
por: Bowen, Tom, et al.
Publicado: (2010)

Cannot write session to /tmp/vufind_sessions/sess_2dvqgq2c43r3f9nom06sn7msa6